{
  "first_published_at": "2011-02-10", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON108685", 
  "title": "Omalizumab: potential risk of arterial thrombotic events", 
  "tags": "{\"parsed_therapeutic\": [\"respiratory-disease-allergy\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Respiratory disease and allergy\"]}", 
  "_document_number": 164, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "respiratory-disease-allergy"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Omalizumab: potential risk of arterial thrombotic events</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: February 2011</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>Use of omalizumab may be associated with an increased risk of arterial thrombotic events. Prescribers should be vigilant for possible thrombotic adverse reactions, and should report these events to us promptly via the Yellow Card Scheme<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Omalizumab (Xolair&#9660;) is a monoclonal antibody, which inhibits immunoglobulin E and is licensed for the treatment of severe persistent allergic asthma in patients (age 6 years or older) in whom standard treatment has failed. Omalizumab is usually administered subcutaneously every 2&ndash;4 weeks. It is available as a 150 mg powder and solvent for solution for injection.</p><h2>Arterial thrombotic events with omalizumab</h2><p>In controlled clinical trials and an unpublished ongoing observational study (EXCELS), a numerical imbalance of arterial thrombotic events (ATEs) was observed in association with use of omalizumab; however, this finding was not statistically significant at the 95% level. ATEs included stroke, transient ischaemic attack, myocardial infarction, unstable angina, and cardiovascular death (including death from unknown cause).</p><p>EXCELS is an ongoing observational study of approximately 5000 patients receiving omalizumab and a control group of approximately 2500 patients not receiving this drug. The study aims to evaluate the clinical effectiveness and long-term safety of omalizumab in patients with moderate to severe asthma followed up for 5 years.</p><p>The table below summarises interim data from EXCELS and data from controlled clinical trials:</p><table class=\"standard\">\r\n\t\t\t<thead>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<th></th>\r\n\t\t\t\t\t<th colspan=\"2\">Arterial thrombotic events per 1000 patient-years of treatment (patient years)</th>\r\n\t\t\t\t\t<th>Risk versus controls: hazard ratio, HR (95% CI)</th>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<th></th>\r\n\t\t\t\t\t<th>Omalizumab</th>\r\n\t\t\t\t\t<th>Controls</th>\r\n\t\t\t\t\t<th></th>\r\n\t\t\t\t</tr>\r\n\t\t\t</thead>\r\n\t\t\t<tbody>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>EXCELS</td>\r\n\t\t\t\t\t<td>5.59 (79/14140)</td>\r\n\t\t\t\t\t<td>3.71 (31/8366)</td>\r\n\t\t\t\t\t<td>Adjusted* HR 1.11 (0.70&ndash;1.76)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr class=\"odd\">\r\n\t\t\t\t\t<td>Controlled clinical trials</td>\r\n\t\t\t\t\t<td>6.29 (17/2703)</td>\r\n\t\t\t\t\t<td>3.42 (6/1755)</td>\r\n\t\t\t\t\t<td>Unadjusted HR 1.86 (0.73&ndash;4.72)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t</tbody></table><p>*Controlling for baseline cardiovascular risk factors</p><h2>Call for reporting</h2><p>Prescribers should be vigilant for possible thrombotic adverse reactions. All suspected adverse reactions, including arterial thrombotic events, to omalizumab&#9660; should be reported via the Yellow Card Scheme at <a href=\"http://www.yellowcard.gov.uk/\">www.yellowcard.gov.uk</a></p><p><strong>Further information:</strong></p><p>BNF section 3.4.2 <a href=\"http://www.medicinescomplete.com/mc/bnf/current/3113.htm\" target=\"_blank\">Allergen immunotherapy</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Feb 2011, vol 4 issue 7: A4.</em><br></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Omalizumab (Xolair&#9660;) is a monoclonal antibody, which inhibits immunoglobulin E and is licensed for the treatment of severe persistent allergic asthma in patients (age 6 years or older) in whom standard treatment has failed. Omalizumab is usually administered subcutaneously every 2&#8211;4 weeks. It is available as a 150 mg powder and solvent for solution for injection.</p><h2>Arterial thrombotic events with omalizumab</h2><p>In controlled clinical trials and an unpublished ongoing observational study (EXCELS), a numerical imbalance of arterial thrombotic events (ATEs) was observed in association with use of omalizumab; however, this finding was not statistically significant at the 95% level. ATEs included stroke, transient ischaemic attack, myocardial infarction, unstable angina, and cardiovascular death (including death from unknown cause).</p><p>EXCELS is an ongoing observational study of approximately 5000 patients receiving omalizumab and a control group of approximately 2500 patients not receiving this drug. The study aims to evaluate the clinical effectiveness and long-term safety of omalizumab in patients with moderate to severe asthma followed up for 5 years.</p><p>The table below summarises interim data from EXCELS and data from controlled clinical trials:</p><table class=\"standard\">\r\n\t\t\t<thead>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<th></th>\r\n\t\t\t\t\t<th colspan=\"2\">Arterial thrombotic events per 1000 patient-years of treatment (patient years)</th>\r\n\t\t\t\t\t<th>Risk versus controls: hazard ratio, HR (95% CI)</th>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<th></th>\r\n\t\t\t\t\t<th>Omalizumab</th>\r\n\t\t\t\t\t<th>Controls</th>\r\n\t\t\t\t\t<th></th>\r\n\t\t\t\t</tr>\r\n\t\t\t</thead>\r\n\t\t\t<tbody>\r\n\t\t\t\t<tr>\r\n\t\t\t\t\t<td>EXCELS</td>\r\n\t\t\t\t\t<td>5.59 (79/14140)</td>\r\n\t\t\t\t\t<td>3.71 (31/8366)</td>\r\n\t\t\t\t\t<td>Adjusted* HR 1.11 (0.70&#8211;1.76)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t\t<tr class=\"odd\">\r\n\t\t\t\t\t<td>Controlled clinical trials</td>\r\n\t\t\t\t\t<td>6.29 (17/2703)</td>\r\n\t\t\t\t\t<td>3.42 (6/1755)</td>\r\n\t\t\t\t\t<td>Unadjusted HR 1.86 (0.73&#8211;4.72)</td>\r\n\t\t\t\t</tr>\r\n\t\t\t</tbody></table><p>*Controlling for baseline cardiovascular risk factors</p><h2>Call for reporting</h2><p>Prescribers should be vigilant for possible thrombotic adverse reactions. All suspected adverse reactions, including arterial thrombotic events, to omalizumab&#9660; should be reported via the Yellow Card Scheme at <a href=\"http://www.yellowcard.gov.uk/\">www.yellowcard.gov.uk</a></p><p><strong>Further information:</strong></p><p>BNF section 3.4.2 <a href=\"http://www.medicinescomplete.com/mc/bnf/current/3113.htm\" target=\"_blank\">Allergen immunotherapy</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update Feb 2011, vol 4 issue 7: A4.</em><br></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2011-02-01", 
  "date_last_modified": "2011-02-08", 
  "_assets": [], 
  "_item_id": 164, 
  "summary": "Use of omalizumab may be associated with an increased risk of arterial thrombotic events. Prescribers should be vigilant for possible thrombotic adverse reactions, and should report these events to us promptly via the Yellow Card Scheme", 
  "body": "Article date: February 2011\n\nOmalizumab (Xolair▼) is a monoclonal antibody, which inhibits immunoglobulin E and is licensed for the treatment of severe persistent allergic asthma in patients (age 6 years or older) in whom standard treatment has failed. Omalizumab is usually administered subcutaneously every 2–4 weeks. It is available as a 150 mg powder and solvent for solution for injection.\n\n## Arterial thrombotic events with omalizumab\n\nIn controlled clinical trials and an unpublished ongoing observational study (EXCELS), a numerical imbalance of arterial thrombotic events (ATEs) was observed in association with use of omalizumab; however, this finding was not statistically significant at the 95% level. ATEs included stroke, transient ischaemic attack, myocardial infarction, unstable angina, and cardiovascular death (including death from unknown cause).\n\nEXCELS is an ongoing observational study of approximately 5000 patients receiving omalizumab and a control group of approximately 2500 patients not receiving this drug. The study aims to evaluate the clinical effectiveness and long-term safety of omalizumab in patients with moderate to severe asthma followed up for 5 years.\n\nThe table below summarises interim data from EXCELS and data from controlled clinical trials:  \n  \n |   | Arterial thrombotic events per 1000 patient-years of treatment (patient years) |   | Risk versus controls: hazard ratio, HR (95% CI) |   \n |   | Omalizumab |   | Controls |   |  |   \n-|-  \nEXCELS |   | 5.59 (79/14140) |   | 3.71 (31/8366) |   | Adjusted* HR 1.11 (0.70–1.76) |   \nControlled clinical trials |   | 6.29 (17/2703) |   | 3.42 (6/1755) |   | Unadjusted HR 1.86 (0.73–4.72) | \n\n*Controlling for baseline cardiovascular risk factors\n\n## Call for reporting\n\nPrescribers should be vigilant for possible thrombotic adverse reactions. All suspected adverse reactions, including arterial thrombotic events, to omalizumab▼ should be reported via the Yellow Card Scheme at [www.yellowcard.gov.uk](http://www.yellowcard.gov.uk/)\n\nFurther information:\n\nBNF section 3.4.2 [Allergen immunotherapy](http://www.medicinescomplete.com/mc/bnf/current/3113.htm)\n\n \n\nArticle citation: Drug Safety Update Feb 2011, vol 4 issue 7: A4.  \n\n"
}